

Frequently Asked Questions for Patients: Hepatitis C Drugs

1. What hepatitis C drugs are funded?

Effective **February 28, 2017**, the following hepatitis C drugs will be added to the Ontario Drug Benefit (ODB) Program for eligible ODB recipients for the treatment of hepatitis C as Limited Use (LU) benefits:

- Harvoni (ledipasvir/sofosbuvir)
- Sovaldi (sofosbuvir)
- Epclusa (sofosbuvir/velpatasvir)
- Zepatier (elbasvir/grazoprevir)
- Daklinza (daclatasvir)
- Sunvepra (asunaprevir)
- Ibavyr (ribavirin)

2. What are these drugs for?

The drugs listed above are for the treatment of chronic hepatitis C.

3. How can I get more information about these drugs?

You can find out more information about these hepatitis C drugs by talking to your doctor and/or your pharmacist.

4. When can patients get coverage for these hepatitis C drugs?

Coverage for these hepatitis C drugs begins on February 28, 2017.

5. I am an ODB recipient and currently receive coverage for a hepatitis C drug through the Exceptional Access Program (EAP). What does this change mean to me?

If you are currently covered for a hepatitis C drug through the EAP, you should complete your therapy with the approved regimen.

6. I am an ODB recipient and am waiting to receive coverage for a hepatitis C drug through the EAP. What does this change mean to me?

If you are currently awaiting an EAP funding decision, you should speak to your physician or health care provider. Beginning on February 28, 2017 you will be able to access hepatitis C therapies without going through the EAP mechanism, if your clinical circumstances meet the funding criteria.

7. Where can I get more information?

For more information about coverage of these hepatitis C drugs, talk to your doctor and/or pharmacist, or email: PublicDrugPrgrms.moh@ontario.ca.